Trial · NCT07912541
ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)
NCT07912541, Not applicable, Not yet recruiting, Advanced MedTech Solutions Pvt. Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE). Trials, record NCT07912541. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912541
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)
- NCT number
- NCT07912541
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Advanced MedTech Solutions Pvt. Ltd.
- Conditions
- Coronary Artery Disease, De Novo Stenosis Lesion, Coronary Stent Implantation
- Interventions
- ADVA ACE Everolimus Eluting Coronary Stent System
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major adverse cardiac events (MACE) - defined as composite of cardiovascular death, non-fatal myocardial infarction (MI), and clinically driven target vessel revascularization (CD-TVR) | 180 days | |
| Secondary | Incidence of Major Advance Cardiac Events 1. Cardiac Death 2. Non- fatal Myocardial Infarction 3. Clinically driven Target Vessel Revascularization | 30 and 360 days | |
| Secondary | Clinically driven target lesion revascularization (CD-TLR) | 30, 180 and 360 days | |
| Secondary | Target vessel failure (TVF) | 30, 180 and 360 days | a composite of Cardiovascular (CV) death, TV-MI and CD-TVR, and individual components of composite end points |
| Secondary | Non-Target Vessel related Myocardial Infarction | 30, 180, and 360 days | |
| Secondary | Stent thrombosis | 0-24 hours, 24 hours-30 days and late 30-365 days | Stent thrombosis as per 1. Academic Research Consortium \[ARC\] 2 Evidence definitions - Definite and probable. 2. As per latency - Acute (0-24 hours), Subacute (24 hours- 30 days) and late (30-365 days) |
| Secondary | Device success | 0 hour, 24 hours, 3 days | Defined as achievement of a final residual stenosis of \<20%, Successful deployment of stent with complete retrieval of delivery system without coronary dissection, device deformation \& visible mal apposition on fluoroscopy with stent boost |
| Secondary | Procedural Success | 0 hour, 24 hours, 3 days | Defined as achievement of a final diameter stenosis of \< 20%(site reported) using any PCI method, without the occurrence of death, MI, or repeat target vessel revascularization during hospital stay. |
| Secondary | Lesion success | 0 hour, 24 hours, 3 days | Defined as achievement of \< 20% residual stenosis using any percutaneous method. |
| Other | QCA Endpoints | 0 and 180 days | Late Lumen Loss |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912541
GET https://conductscience.org/api/trials/v1/NCT07912541/registered